The present invention is concerned with
deuterium-enriched sulfonamides of formula 1, their pharmaceutically acceptable salts and methods of use thereof for the treatment of
anxiety disorders including, General
Anxiety Disorder (GAD),
Panic Disorder (PD), Post-Traumatic Stress Disorder (PTSD), Social Phobia (SP), Health
Anxiety (Hypochondriasis), depression, major depressive disorders, unipolar depression, bipolar I depression disorder, bipolar II depression disorder, treatment-resistant depression, single episodic and recurrent major depressive disorders, depression in the medically ill,
attention deficit hyperactivity disorder (ADHD),
attention deficit disorder (ADD), Obsessive-Compulsive Disorder (OCD), Obsessive-Compulsive Personality Disorder (OCPD),
Autism Spectrum Disorder (ASD),
schizophrenia,
psychosis,
epilepsy, seizures, hot flashes due to
menopause, age-related
macular degeneration (AMD), premature ejaculation,
male erectile dysfunction,
sexual dysfunction,
obesity,
eating disorders,
bulimia nervosa,
anorexia nervosa,
angina,
migraine, pain,
nociception, sleep disorders,
insomnia,
fibromyalgia,
alcohol withdrawal,
autism, Rett'
s syndrome, cyclothymic disorder, neural injury, neurodegenerative diseases, Parkinson's
disease, Parkinson's
disease psychosis, Huntington
disease, Alzheimer's disease,
frontotemporal dementia,
cognitive impairment associated with age-related
dementia, Alzheimer's disease,
schizophrenia,
psychosis, depression, pain or discomfort associated with
surgery and pain or discomfort associated with
medical illness.